Pyrazolone compounds useful for treatment of cerebrovascular disorders associated with ischemic stroke

Patent metadata

Field	Value
Publication number	US-9259416-B2
Application number	US-65979905-A
Country	US
Kind code	B2
Filing date	Aug 10, 2005
Priority date	Aug 10, 2004
Publication date	Feb 16, 2016
Grant date	Feb 16, 2016

Abstract

A drug for the treatment of cerebrovascular disorders associated with insufficient cerebral circulation such as ischemic stroke, which comprises a pharmaceutically effective amount of a pyrazolone compound of structural Formula (I):

or a pharmaceutically acceptable salt thereof, or a pseudo-polymorphic form thereof, administered at a controlled dose so that the plasma concentration of unchanged form is kept constant for a predetermined period of time and so that the compound may exhibit a higher effect.

First claim

The invention claimed is:

1. A method for the treatment of a brain with acute ischemic stroke, or a method for the treatment of a brain after acute ischemic stroke to reduce cerebral infarcts, comprising administration to a patient in need of such treatment of a therapeutically effective amount of 3-methyl-1-phenyl-2-pyrazolin-5-one, which comprises an administration of a loading dose by intravenous bolus administration which is finished within about five minutes and an administration of a maintenance dose by intravenous continuous administration for about 24 hours to 120 hours, wherein the dose administered by the loading dose administration is about 0.05 to about 0.5 mg per kg of the weight of a patient, and the dose administered by the administration of the maintenance dose is about 0.125 to about 2.0 mg/hr per kg of the weight of the patient.

2. The method according to claim 1 , wherein the duration of the administration of the maintenance dose is about 24 hours to about 72 hours.

3. The method according to claim 1 , wherein the dose administered by the loading dose administration is selected from the group consisting of about 0.075 to about 0.4 mg per kg of the weight of a patient and about 0.1 to about 0.3 mg per kg of the weight of a patient.

4. The method according to claim 1 , wherein the dose administered by the administration of the maintenance dose is selected from the group consisting of about 0.15 to about 1.0 mg/hr per kg of the weight of the patient and about 0.25 to about 0.75 mg/hr per kg of the weight of the patient.

5. A method for the treatment of a brain with acute ischemic stroke, or a method for the treatment of a brain after acute ischemic stroke to reduce cerebral infarcts, comprising administration, to a patient in need of such treatment, of a loading dose and a maintenance dose of a therapeutically effective amount of 3-methyl-1-phenyl-2-pyrazolin-5-one, wherein the administration of the loading dose is intravenous bolus administration which is finished within about five minutes, and further wherein the dose administered by the loading dose administration is selected from the group consisting of about 0.05 to about 0.5 mg per kg of the weight of a patient and about 0.075 to about 0.4 mg per kg of the weight of a patient; the dose administered by the administration of the maintenance dose is selected from the group consisting of about 0.125 to about 2.0 mg/hr per kg of the weight of the patient, about 0.15 to about 1.0 mg/hr per kg of the weight of the patient, and about 0.25 to about 0.75 mg/hr per kg of the weight of the patient; and the maintenance dose is administered by intravenous infusion administration for a duration which is selected from the group consisting of about 120 hours, about 72 hours, and about 24 hours, after initiation of administration of the maintenance dose.

6. The method according to claim 5 , wherein patients in need of such treatment are determined by NIH stroke scale of not more than 22, or by a method of determination for neurological criticality corresponding to the NIH stroke scale of not more than 22.

7. The method according to claim 1 , wherein a duration of the administration of the maintenance dose is 72 hours to 120 hours.

Assignees

• Yuki Satoshi
• Nakano Takuma
• Suzuki Hiroko
• Mitsubishi Tanabe Pharma Corp

Inventors

• Yuki Satoshi
• Nakano Takuma
• Suzuki Hiroko

Classifications

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P25/02

  for peripheral neuropathies · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• A61K2039/545

  characterised by the dose, timing or administration schedule · CPC title

• A61P25/14

  for treating abnormal movements, e.g. chorea, dyskinesia · CPC title